Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook

Core Insights - The article emphasizes the strong performance of biotech stocks, highlighting a 137.6% increase in the Top Picks over the last year and a compound annual growth rate (CAGR) of 37.2% since 2017 [1]. Biotech Sector Performance - The biotech Top Picks have shown significant growth, with a 137.6% increase last year [1]. - The core portfolio, referred to as LTGP, has achieved a mid-20s CAGR, indicating robust long-term performance [1].